Medical and Science
National consultation to set MRFF medical research priorities

Medical News: A national consultation process will guide the third set of the Morrison Government’s ground-breaking Medical Research Future Fund (MRFF) Australian Medical Research and Innovation Priorities for 2020–2022.
This consultation process will ensure the MRFF continues to target national health priorities for better health outcomes.
Nadia Levin, CEO and Managing Director said “With the MRFF reaching full capitalisation of $20 billion this year, it plays as key funding role for all stages of Australian health and medical research. As we have throughout the history of MRFF, Research Australia will be engaging closely in the development of the next set of priorities to ensure that all stages of the medical research pipeline can benefit. It will be central to growing our sector and positioning Australia as a global leader in health and medical research and innovation.”
Determining future health priorities is about taking into account the burden of disease in Australians and the need to enhance the translation of research into clinical practice.
Australia’s health and medical researchers are world class and the Government continues to drive investment in ways that deliver the practical benefits of medical research and innovation to all Australians.
The landmark $20 billion MRFF is enhancing this growth in Australia’s cutting-edge health and medical research.
It is leading to new cures and treatments across Australia—saving lives and improving lives. The Australian public, organisations with expertise in health and medical research and innovation, consumer representatives, clinicians and health services managers are invited to contribute to the consultation.
Consultation is now open to inform the development of the Medical Research Future Fund (MRFF) Australian Medical Research and Innovation Priorities for 2020–22.
The Australian Medical Research Advisory Board is seeking comment from interested parties through online submissions and public webinars until 7 October 2020.
Visit the Department of Health’s Consultation Hub to see how you can comment online.
News & Trends - Pharmaceuticals

Clinicians shift stance, join calls for PBS subsidy of obesity and weight-loss medicines
Over a third of Australian adults live with obesity, and the National Obesity Strategy estimates the direct and indirect costs […]
MoreNews & Trends - Pharmaceuticals

Astellas secures new indication for prostate cancer drug
Astellas Xtandi (enzalutamide) is now TGA registered for a new indication for patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with […]
MoreNews & Trends - MedTech & Diagnostics

Stakeholder calls intensify as government stalls on genetic discrimination ban
Calls have intensified for the federal government to honour its commitment to outlaw genetic discrimination in life insurance, as stakeholders […]
MoreNews & Trends - MedTech & Diagnostics

Pressure mounts to expand home-based therapies in kidney disease: World Kidney Day
As Australia marks World Kidney Day, the stark reality is that one in three adults is at risk of chronic […]
More